Global Hyperphosphatemia Market Insights Forecasts to 2030

• The Hyperphosphatemia Market was valued at USD 3.1 Billion in 2021.
• The Market is Growing at a CAGR of 6.5% from 2022 to 2030
• The Worldwide Hyperphosphatemia Market is expected to reach USD 4.2 Billion by 2030
• Europe is expected to grow the fastest during the forecast period.

The Global Hyperphosphatemia Market is expected to reach USD 4.2 Billion by 2030, at a CAGR of 6.5% during the forecast period 2022 to 2030.

When there is an excessive amount of phosphate in the blood, a condition known as hyperphosphatemia occurs. Those with chronic renal disease and cardiovascular disorders may exhibit an abnormally high level of phosphate. Hyperphosphatemia is a major factor in both morbidity and mortality in people with chronic renal disorders. Hyperphosphatemia is a condition where the body has an abnormally low level of phosphates, which can lead to a variety of issues include confusion, appetite loss, bone discomfort, and bone fractures.

Phosphate is found in body parts like bones, teeths, inside the cells and also in the blood. Not only this, but kidneys also function well due to the phosphate content in the body. But certain diseases or complications may lead to impairment of kidney that results to immense high level of phosphate in blood. Hyperphosphatemia is a common problem in people having chronic kidney disease which is end stage kidney problem. Various other causes of hyperphosphatemia are diabetic ketoacidosis, high vitamin D levels, uncontrolled diabetes, and low parathyroid hormone levels.

COVID 19 Impact on Hyperphosphatemia Market

With the onset of COVID 19, millions of people were affected across 150 countries globally. And governments has adopted certain measures to get rid of this issue. The COVID 19 pandemic has played a significant role in hampering the growth of the Hyperphosphatemia market. The pandemic has resulted into the disruption of the overall supply chain and also hampered the smooth functioning of businesses. In addition, COVID 19 has adversely impacted the patient population owing to the higher hospitalization as well as mortality rates which has impacted the revenue rates of the market.

Key Market Drivers

Increasing number of patients who are on dialysis to increase the demand of market

The rise in the number of chronic kidney problems worldwide is one of key factors that is contributing the growth of the market. The pressure of CKD is increasing exponentially and is going to increase over the upcoming years. In fact, it is going to be one of the common causes of deaths over the coming years. According to the report shared by National Kidney Foundation Inc., in the year 2018around 7,85,883 Americans suffered from kidney failure and opted for dialysis and kidney transplant. Most of the people who are undergoing dialysis witnessed hyperphosphatemia after a certain point of time. A report of National Center for Biotechnology Information (NCBI) stated that 80% to 85% of the dialysis dependent people  experienced hyperphosphatemia who are then treated with phosphate binders. Thus, increasing number of chronic kidney diseases are driving the market growth.

Rising number of products launching in developing countries propelling the market growth

The rise in the number of product launches across developing countries is going to propel the global hyperphosphatemia market growth. For example, In April 2021, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has generated positive results from a phase III study in China for Velphoro (PA21) to reduce serum phosphorous in geriatric patients. In addition, in July 2020, Emcure Pharmaceuticals introduced first ever generic version of sucroferric oxhydroxide (Dynulta) in India to treat hyperphosphatemia. Thus, increasing number of approval of products are going to drive the market growth in developing countries.

Restraining Factors

Poor Medication adherence among due high pill burden to restrain the market growth

The poor adherence to treatment owing the burden of high pill among patients undergoing dialysis are hampering the market growth. For instance, according to the article published by the National Center for Biotechnology Information (NCBI), a dialysis dependent patient take around 10 to 12 types of medicines which results into the side effects of gastrointestinal intolerance. Thus, these factors are going to hamper the use of phosphate binders among CKD patients.

Key Market Challenges

Poor understanding of products

As already discussed, high level of phosphate can result in serious health issues like kidney problems and diabetes. The hyperphosphatemia is anticipated to grow at a rapid pace but there are certain factors which can be challenging such as poor knowledge of phosphate content in food products and the lack of knowledge on phosphate management and increasing competition among the market players make it extremely difficult to manage.

Key Market Opportunities

New market players developing the market growth

Due to the technological advancements in the hyperphosphatemia industry, many companies have started entering into the industry which is increasing the competition. Hence, to stay ahead in the race, the companies are investing heavily on research and development. For instance, Shield Therapeutics aims to develop products which treat hyperphosphatemia and iron deficiency anemia. The highest selling product of the company is Feraccru. Apart from this, the company has also introduced PT30 which offer hypoallergenic IV iron therapy.

Market Segmentation

Product Insights

Sevelamer segment holds the largest market share over the forecast period.

On the basis of product, the global hyperphosphatemia market is segmented into sevelamer, calcium based phosphate binders, iron based phosphate binders, non phosphate binders, lanthanum carbonate, and others. Among these, the sevelamer segment is dominating the market with the largest market share over the forecast period. One of the main factors predicted to fuel market revenue growth is the growing demand for the product as a result of the increase in renal disease cases. The medicine is effective and well-tolerated by both, which broadens the range of its application. It is used to treat cases involving patients receiving haemodialysis as well as for people with chronic kidney illnesses.

Iron based phosphate binders, on the other hand have witnessed a second largest growth due to the limited documental evidence for the safety profile of long duration usage of sevelamer. Apart from this, the launch of the new branded and generic products by the key companies driving the market expansion in the developed as well as developing countries.

Distribution Channel Insights

Hospital Pharmacy segment to dominate the market with the highest market share over the forecast period.

On the basis of distribution channel, the global hyperphosphatemia market is segmented into hospital pharmacy, online pharmacies, and retail pharmacies. Among these, the hospital pharmacy segment is anticipated to dominate the market with the highest market share over the forecast period owing to the increasing number of patients looking dialysis in hospitals across the world. Apart from this, the developing countries like China and India have seen surge in the number of dialysis dependent patients. Hence, results in the segmental growth.

The online stores on the other hand is anticipated to forsee the highest CAGR over the upcoming years owing to patients shifting the capital cities towards online platform for procurement of drugs in the hyperphosphatemia treatment which has resulted in the segmental growth.

Regional Insights

North America dominates the market with the largest market share over the forecast period.

Due to an ageing population and an increase in incidences of chronic renal disease, North America is anticipated to have the greatest market for drugs that treat hyperphosphatemia. Some of the important North American nations with a high contribution rate to this sector include the United States, Canada, and Mexico. The Asia Pacific region, which includes nations like China, Japan, and India, is anticipated to experience the quickest growth in the market for Hyperphosphatemia Medications. Other countries that are projected to experience growth include Germany, Italy, and France.

Due to low healthcare spending rates, a lack of public knowledge, and a high need-based approach to treatment alternatives in this region, the Middle East and Africa are anticipated to have the smallest market for Hyperphosphatemia Medications. The main contributors to this region include nations like Saudi Arabia, South Africa, and the United Arab Emirates.

Key Market Developments

• In April 2021, Ardelyx, Inc. has made an announcement about its partnership with a Japanese company named Kyowa Kirin Co. Ltd. Both of these companies have started Phase 3 clinical studies to evaluate tenapanor for hyperphosphatemia.
• In April 2021, Vifor Fresenius Medical Care Renal Pharma has generated positive results from a phase III study in China by evaluating the efficacy of Velphoro.

List of Key Market Players

• Amag Pharmaceuticals
• Johnson and Johnson
• Keryx Biopharmaceuticals
• DSM Biotech Pharmacal
• Sun Pharm Inc.
• Zeria Pharmaceutical
• Bruno Pharmaceutical Spa
• Fermenta Biotech Ltd
• Pfizer Inc.
• Roche Diagnostics Corporation

Market Segment

This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global Hyperphosphatemia market based on the below-mentioned segments:

Hyperphosphatemia Market, Product Analysis

• Sevelamer
• Calcium based phosphate binder
• Iron based phosphate binders
• Lanthanum carbonate
• Non phosphate binders
• Others

Hyperphosphatemia Market, Distribution Analysis

• Hospital pharmacy
• Retail pharmacy
• Online stores

Hyperphosphatemia Market, Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa